Impact News +++ Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System (Zacks) +++ MICROBOT Aktie +4,25%

OXFORD BIOMEDICA Aktie

>OXFORD BIOMED Performance

1 Woche: +0,8%

1 Monat: +30,0%

3 Monate: +68,0%

6 Monate: +86,4%

1 Jahr: +67,1%

laufendes Jahr: +26,5%

>OXFORD BIOMEDICA Aktie

Name:

OXFORD BIOMEDICA LS-,50

Land:

Großbritannien

Sektor:

Gesundheit

ISIN/ Wkn:

GB00BDFBVT43 / A2JLRX

Symbol/ Ticker:

OXOA (Frankfurt)

Kürzel:

FRA:OXOA, ETR:OXOA, OXOA:GR

Index:

Webseite:

http://www.oxfordbiomedic..

Profil:

Oxford Biomedica plc is a leading gene and cell th..
>Volltext..

Marktkapitalisierung:

816.85 Mio. EUR

Unternehmenswert:

879.16 Mio. EUR

Umsatz:

137.04 Mio. EUR

EBITDA:

-23.55 Mio. EUR

Nettogewinn:

-45.95 Mio. EUR

Gewinn je Aktie:

-0.44 EUR

Schulden:

115.72 Mio. EUR

Liquide Mittel:

64.53 Mio. EUR

Operativer Cashflow:

-53.87 Mio. EUR

Bargeldquote:

1.04

Umsatzwachstum:

50.73%

Gewinnwachstum:

71.26%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

OXFORD BIOMEDICA, OXFORD BIOMED

Letzte Datenerhebung:

09.09.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 120.17 Mio. St.

Frei handelbar: 68.83%

Leerverk. Aktien: 0.59%

Rückkaufquote: -2.28%

Mitarbeiter: 861

Umsatz/Mitarb.: 0.16 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: -4.26%

Bewertung:

KGV: -

KGV lG: -

KUV: 5

KBV: 10.3

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 40.9%

Gewinnmarge: -33.53%

Operative Marge: -34.87%

Managementeffizenz:

Gesamtkaprendite: -17.85%

Eigenkaprendite: -65.91%

>Peer Group

Es sind 81 Aktien bekannt.

>OXFORD BIOMED Chart & Kurs - Stuttgart

>OXFORD BIOMED News

23.06.25 - 15:24	Oxford Biomedica acquires last 10pc stake in US subsidiary (ShareCast)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

23.06.25 - 13:06	Oxford BioMedica completes purchase of last 10% stake in US subsidiary (Alliance)
	Oxford BioMedica PLC on Monday said it has completed the acquisition of the remaining 10% stake in its US subsidiary from Massachusetts, US-based biotechnology firm......

11.06.25 - 12:00	Oxford BioMedica touts strong first-half momentum ahead of meeting (Alliance)
	Oxford BioMedica PLC reported 'strong commercial momentum' during the first half of the year, in a statement ahead of its annual general meeting on Wednesday.The......

09.04.25 - 10:36	Oxford Biomedica annual loss narrows; hails ′commercial momentum′ (Alliance)
	Oxford BioMedica PLC on Wednesday said its client portfolio continued to expand and diversify, noting it was on track to achieve 'significant' revenue growth consistent......

09.04.25 - 10:12	Oxford Biomedica FY24 Net Loss Narrows; Sees Profitability, Higher Revenues In FY25; Stock Down (AFX)
	LONDON (dpa-AFX) - Oxford Biomedica plc (OXB.L), a gene and cell therapy company, on Wednesday reported that its net loss narrowed in fiscal 2024 compared with the last year, with growth in revenu......

09.04.25 - 09:30	Oxford Biomedica falls on lower EBITDA outlook despite strong revenue guide (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

27.03.25 - 08:06

ViroCell Biologics Appoints Viral Vector Expert as Special Advisor (Business Wire)

James Miskin brings 25 years of cell and gene therapy experience to an advisory role focused on further unlocking ViroCell's potential LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the appointment of James Miskin as a Special Advisor. James will leverage expertise gained from a 25-year career in CGT to support ViroCell's continued growth and technical development. James spent over 23 years at Oxford Biomedica (OXB), with executive leadership roles initially as Chief Technical Officer (CTO) and then Chief Quality and Technical Officer (CQTO). As an executive leader at OXB James held overall responsibility for a range of key functions including Programme and Alliance Management, Process Development, GMP analytics, Quality, Manufacturing, MSAT, Validation and CMC Regulatory. James ha...

17.02.25 - 12:36	Oxford BioMedica shares fall as revenue to stay below 2022 level (Alliance)
	Oxford BioMedica PLC on Monday said it was confident of delivering 'another year of strong progress,' noting strength of demand. The Oxford, England-based cell and......

17.02.25 - 09:36	Oxford Biomedica Expects FY24 Revenue Of GBP 127 Mln - GBP 129 Mln (AFX)
	LONDON (dpa-AFX) - Biotechnology company Oxford Biomedica Plc (OXB.L) announced on Monday that it expects to record revenues between 127 million pounds to 129 million pounds in fiscal 2024. The ex......

23.09.24 - 11:21	Oxford Biomedica posts strong revenue growth in first half results (DailyMail)
	OXB maintained its 2024 earnings outlook after reporting strong revenue growth in the first half of the year....

23.09.24 - 09:07	Oxford BioMedica H1 Loss Narrows, Revenues Climb; Confirms FY24, Medium-term Outlook (AFX)
	LONDON (dpa-AFX) - Oxford Biomedica plc (OXB.L) Monday reported first-half loss before tax of 35.74 million pounds, narrower than last year's loss of 52.34 million pounds. The narrower loss mainly......

23.09.24 - 08:54	BUSINESS LIVE: REA ups Rightmove offer; Galliford Try gains contract; Oxford Biomedica losses fall (DailyMail)
	Among the companies with reports and trading updates today are Rightmove, Galliford Try, Oxford Biomedica, AstraZeneca, Schroders, and Legal & General....

18.09.24 - 13:06	Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO (GlobeNewswire EN)
	Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO...

02.09.24 - 13:54	Oxford Biomedica Says Lucinda Crabtree Joins As CFO (AFX)
	LONDON (dpa-AFX) - Oxford Biomedica Plc (OXB.L) said on Monday that, as previously announced, Lucinda Crabtree has joined the company as Chief Financial Officer on September 2 to replace Stuart Pa......

02.09.24 - 13:03	Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today (GlobeNewswire EN)
	Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ich habe die Tradition im Griff und die Zukunft im Auge. - Herbert Föttinger

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram